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Aim: To review the most important moral challenges following from the widespread use of bariatric surgery
for type 2 diabetes for patients with BMI b35 kg/m2, although high quality evidence for its short and long
term effectiveness and safety is limited.
Methods: Extensive literature search to identify and analyze morally relevant issues. A question based method
in ethics was applied to facilitate assessment and decision making.
Results: Several important moral issues were identiﬁed: assessing and informing about safety, patient
outcomes, and stakeholder interests; acquiring valid informed consent; deﬁning and selecting outcome
measures; stigmatization and discrimination of the patient group, as well as providing just distribution of
health care. The main sources of these challenges are lack of high quality evidence, disagreement on clinical
indications and endpoints, and the disciplining of human behavior by surgical interventions.
Conclusion: A lack of high quality evidence on the effect of bariatric surgery for the treatment of T2DM in
patients with BMI b 35/kg/m2 poses a wide variety of moral challenges, which are important for decisions on
the individual patient level, on the management level, and on the health policy making level. Strong
preferences among surgeons and patients may hamper high quality research.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Type 2 diabetes mellitus (T2DM) is one of the most challenging
health problems in the world (UN General Assembly, 2006), affecting
more than 300million people worldwide, a ﬁgure which is expected to
increase by more than 50% in the next decade (Danaei et al., 2011;
World Health Organization, 2006). Many types of treatments exist, but
some surgical procedures in morbidly obese subjects appear to have
dramatic beneﬁcial effects on T2DM. According to a 1991 National
Institutes of Health consensus statement, bariatric surgery may
potentially improve T2DM (Consensus Development Conferencepublic obesity resource center
ith experience from bariatric
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nc. Open access under CC BY-NC-ND liPanel, 1991), whilst international conferences on bariatric surgery for
T2DMhave concluded that bariatric surgery is an effective treatment of
T2DM inmorbidly obese subjects (Rubino, Kaplan, Schauer, Cummings,
& Delegates, 2010). Recently, bariatric surgery has been launched as an
attractive treatment alternative for patients with T2DM and a body-
mass index (BMI) b35 kg/m2 (Dixon, Pories, O'Brien, Schauer, &
Zimmet, 2008; Rubino, 2008; Rubino et al., 2010;Mingrone et al., 2012;
Varela, 2011; Spanou, 2013; Walton & Date, 2011). Several observa-
tional and some randomized controlled studies demonstrate that such
surgical procedures may help patients to achieve a substantial weight
loss, ameliorate glucose control andeven induce remissionof T2DMin a
large proportion of patients (Buchwald et al., 2009; Dixon et al., 2008;
Lautz, Halperin, Goebel-Fabbri, & Goldﬁne, 2011).
However, there is still debate on the limited evidence on the effect
and safety of bariatric surgery in persons with BMI b 35 kg/m2
(Colquitt, Picot, Loveman, & Clegg, 2009; Institute of Health Economics,
2011; Lautz et al., 2011; Pinkney & Kerrigan, 2004), particularly in those
with T2DM. Some critics argue that the remission of T2DMafter surgery
is often transient (Pinkney, Johnson, & Gale, 2010). Even with high
quality evidence for morbidly obese persons, we cannot uncritically
extrapolate results on T2DM from persons with BMI ≥ 35 kg/m2 to
those with BMI b 35 kg/m2 (Dixon et al., 2012). The long-term effects
on glucose control and surrogate endpoints such as albuminuria, lipidcense.
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cular risk factors of the various bariatric procedures are still not fully
understood (Lautz et al., 2011; Varela, 2011). Hence, it is still
controversial whether bariatric surgery is a justiﬁed treatment strategy
for T2DM in patients with BMI b 35 kg/m2 (Lautz et al., 2011).
Moreover, bariatric surgery modiﬁes otherwise healthy organs
with partly irreversible methods, and may forcefully alter people's
everyday behavior. Some patients feel guilt and shame after bariatric
surgery (Groven & Raheim, and Engelsrud). Bariatric surgery itself has
been considered by some to be a part of the medicalization of modern
life, transforming physical states into diseases, persons into patients,
and behavioral problems into surgical tasks (de Vries, 2007).
Furthermore, some have argued that bariatric surgery is governed
by overtly strong professional and commercial interests (Pinkney,
2010a) launching value laden terms, such as “metabolic surgery” and
“diabetic surgery.” History bears witness to a series of futile surgical
procedures, including within the ﬁeld of bariatric surgery (Pinkney et
al., 2010). Jejunoileal bypass, for example, was performed for many
years before severe procedure-related complications were recognized
(MacDonald, 2003).
These circumstances all pose substantial moral questions to those
who care for and advice persons with diabetes. Accordingly, the
objective of this review is to highlight the most pertinent moral
questions with bariatric surgery for patients with T2DM and
BMI b 35 kg/m2 so that health professionals, decision makers, and
health policy makers can make sound and transparent decisions on
which treatment strategies should be offered, to which patients and
patient groups in order to help them in the best possible way.
2. Method
A question based (Socratic) approach in ethics is used where a set
of 32 questions is posed in order to highlight moral issues connected
to bariatric surgery for diabetes. The method is described in detail
elsewhere (Hofmann, 2005a) and has been implemented in models
addressing ethical issues in Health Technology Assessment (HTA)
(HTA core model for medical & surgical interventions v 1). The
approach has been applied to other analyses of ethical aspects of a
wide range of health technologies as well as to other surgical
procedures (Hofmann, 2010).
The core of the question based approach is to identify moral issues
and reveal underlying or hidden moral assumptions in order to
stimulate critical thinking and sound decision making. Rather than
analyzing bariatric surgery for T2DM within a particular ethical
framework and providing speciﬁc recommendations, the method
aims at presenting the norms, values, viewpoints, and ethical
arguments that are relevant for recommendations and decisions in
context. Hence, the method is not a tool for producing clear-cut
answers to all challenging questions from an ethics ivory tower, but
provides norms, values, and arguments that health professionals and
decision makers may need to take into account when selecting the
best treatment option for this group of patients.
A literature search method developed to identify relevant moral
issues was applied. MEDLINE, EMBASE, EURETH, Cochrane, BIOSIS,
CINAHL, and PSYCINFO were included in this search. Search
command and strategy building followed thereafter (Droste,
Dintsios, & Gerber, 2010). Search words were: bariatric surgery,
type 2 diabetes, ethic*, moral*, patient autonomy, consent, assent,
conﬂict, interest, self determination, health disparities, discrimina-
tion, mental capacity, mental competency, parental, perceptive
discrimination, beneﬁcence, utility, effectiveness, efﬁcacy, effective-
ness, safety. Due to limited results for BMI b35 kg/m2, searches were
performed without this limitation and the literature was assessed
manually for BMI-ranges. Some results (moral issues) from literature
without BMI-limitations were found relevant also for BMI b35 kg/
m2 and were included.An initial literature search, informal interviews with experts, and
scanning of patient interest groups' web-pages helped us identify 13
(of 32) questions as morally relevant. Then literature searches were
performed to address these 13 questions. On closer scrutiny, 5 were
excluded, as they were not considered to be special to bariatric
surgery for T2DM with BMI b 35 kg/m2. Duplicates of moral issues or
arguments were excluded. So were studies only mentioning ethical
issues, but without any substantiation of these.
3. Results
232 articles and reports were identiﬁed. 68 articles were included
in the analysis on the basis that they provided information on a series
of moral issues related to the following questions Q1–8. Fig. 1
illustrates the results from the search strategy.
3.1. Q1. Is bariatric surgery a safe and effective means of treating T2DM?
Despite the overwhelming number of studies, it is argued that the
evidence is of too poor a quality (Colquitt et al., 2009; Institute of
Health Economics, 2011; Lautz et al., 2011; Picot et al., 2009; Pinkney &
Kerrigan, 2004). Several meta-analyses of the effects of bariatric
surgery have been excluded from systematic reviews and health
technology assessments because they include only case series and
studies of poor and mediocre quality (Colquitt et al., 2009; Institute of
Health Economics, 2011). Although several studies have indicated that
bariatric surgery is effective in the treatment of diabetes (Lee et al.,
2011; Mingrone et al., 2012; Schauer et al., 2012) and can provide
“complete disease remission” (Rubino, Moo, Rosen, Dakin, & Pomp,
2009), most studies are case series or retrospective cohort studies. Only
a few randomized trials exist (Dixon et al., 2008; Ikramuddin et al.,
2013; Keidar et al., 2013; Mingrone et al., 2012; Schauer et al., 2012), of
which most are small and report short-term outcome (Colquitt et al.,
2009; Institute of Health Economics, 2011; Lautz et al., 2011; Picot et al.,
2009), particularly for patients with BMI b 35 kg/m2. A recent meta-
analysis is based on a restricted number of small-scale short-term trials,
with a substantial risk of publication bias (Li et al., 2012). In addition,
few studies have included control groups which are offered an
appropriate standardized intensive lifestyle intervention program
(Hofso et al., 2010). High quality long-term studies on safety are
lacking, so that studies on cost effectiveness provide uncertain results.
Studies call attention to the risk of serious adverse events (Keidar et al.,
2013). Accordingly, extrapolating results from bariatric surgery for
patients with BMI ≥ 35 kg/m2 to BMI b 35 kg/m2 may not be
warranted (Dixon et al., 2012). Moreover, the mechanisms by which
gastrointestinal surgery may ameliorate T2DM, and whether they are
independent of their effects on food intake and body weight, are still
largely unknown (Lautz et al., 2011).
The lack of long-term high quality evidence for the effects of
bariatric surgery on T2DMmakes it difﬁcult to answer the question of
whether it is effective, safe and efﬁcient, making decision-making
demanding. It may well be morally commendable to treat individual
overweight or obese patients with T2DM at centers that can
document good results in long-term case series studies. However,
whether bariatric surgery should be implemented and funded as a
general method to treat T2DM for persons with BMI b 35 kg/m2 is a
difﬁcult moral question. Therefore there is a moral imperative to
provide high quality evidence on the efﬁcacy, effectiveness, safety,
and cost-effectiveness of bariatric surgery before wider access to this
treatment strategy can be given (Hofmann, 2012).
3.2. Q2. What is the goal of the treatment?
Which endpoint to select, monitor, and report is a scientiﬁc
question, but it is also a moral question, as the endpoints indicate the
goal of the treatment, and what is considered to be a good life. A
Fig.1. Results from literature search.
599B. Hofmann et al. / Journal of Diabetes and Its Complications 27 (2013) 597–603variety of endpoints are reported in studies of diabetes surgery:
improvements in multiple metabolic measures (such as glucose
tolerance, percent glycosylated hemoglobin, insulin sensitivity, beta-
cell function), short-term reductions in the use of antidiabetic drugs,
remission of T2DM, weight loss, cardiovascular events, and mortality
(Buchwald et al., 2009; Dixon et al., 2008; Lautz et al., 2011; Pinkney
et al., 2010). Other surrogate endpoints are changes in albuminuria,
blood lipids, blood pressure, inﬂammation markers, and other
cardiovascular risk factors (Lautz et al., 2011). Weight-loss might be
an unreliable surrogate endpoint for improved glucose control in
diabetes (Pinkney et al., 2010), for as surgery advocates argue,
diabetes can be cured before weight loss after surgery (Rubino et al.,
2009). How endpoints are deﬁned is also important. The deﬁnition of
remission of T2DM, for example, has important implications for the
effect size (Buse et al., 2009; Pournaras et al., 2012).
Some studies have shown stable improvements in health-related
quality of life (Tayyem, Ali, Atkinson, &Martin, 2011),while others have
shown that initial mental health beneﬁts tend to either dissipate after
3 years (Pinkney et al., 2010) or be closely related to long-termweight
loss outcome (Karlsson, Taft, Rydén, Sjöström, & Sullivan, 2007). The
same variety in goals exists for the monitoring of complications. The
potential beneﬁcial effects of surgery on T2DMmight be offset by short
and long-term complications. Clinically important long-term results
after surgery, such as changes in levels of micronutrients, bonemineral
density and fracture risk, microvascular and macrovascular complica-
tions, (Lautz et al., 2011), are largely unknown. Further, postprandial
hypoglycemia ranging from moderate to severe, has been increasingly
recognized after bariatric surgery (KE, 2011), particularly following
gastric bypass. Symptomatic hypoglycemia requiring hospitalisation
was nearly 3-fold higher among patients who had undergone gastric
bypass than a matched control group from the general population
(Marsk, Jonas, Rasmussen, & EN, 2010). A Norwegian study of 64
patients undergoing gastric bypass showed that 1 out of 4 had
postchallenge hypoglycemia 1 year after the GB procedure (Hofsø et
al., 2011). Amorally relevant question is therefore whether this limited
knowledge is due to a lackof complex researchdesign, research funding,
ignorance, or limited interest in such issues. The deﬁnition and selection
of an appropriate endpoint are therefore both moral as well as
professional issues, as is the selection of inclusion criteria.Additionally, the question of who decides the endpoints is as
morally important, as the endpoints express the goal of treatment and
what is considered to be good and healthy. Patients should have a say
in decisions on endpoints, especially when evidence is poor.
3.3. Q3. What are the interests of the stakeholders?
Both professionals and patients have strong and partly coinciding
interests, and it is argued that there are professionals “who perform
surgery for personal proﬁt within a largely unregulated environment”
(Pinkney et al., 2010). Conﬂicts of interest may arise as surgeons and
scientists hold positions in or are paid by commercial companies
providing products for bariatric surgery. Private for proﬁt bariatric
centers may let non-medical motives interfere with medical in-
tentions. Moreover, enthusiasm sometimes exceeds evidence, and
may compromise the search for high quality scientiﬁc evidence.
Differences in professional standards and preferences between
funding systems, nations, and regions indicate that professional
interests vary. E.g., gastric banding techniques dominate in Australia,
while gastric bypass is frequently performed in the United States. The
variability of procedures also appears to have substantial moral
consequences. Learning and handling a large variety of procedures
may expose patients to inferior quality treatment (Ballantyne et al.,
2005). On the other hand, restricting the number of procedures may
limit the possibility to adjust treatment to the individual patient.
Patients are active on the Internet and patient organizations may
inﬂuence the medical industry (Jones, 2008; Oliver, 2006), although it
is not obvious that it serves the best interest of the individual (and
vulnerable) patient (Meier, 2009). Some diabetes associations have
greeted bariatric surgery with caution (American Diabetes Associa-
tion, 2010; International Diabetes Federation, 2011). Hence, stake-
holder interests should be open and transparent to promote sound
and accountable decisions.
3.4. Q4. Are there moral challenges connected to informed consent?
3.4.1. Lack of knowledge to support information
As the evidence for the long-term effectiveness and safety of
bariatric surgery for T2DM in patients with BMI b35 kg/m2 is limited,
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informed consent. Information pertaining to disease etiology, mech-
anisms and outcomes from various interventions is complex, even to
specialists caring for patients undergoing bariatric treatment, and is
difﬁcult to communicate to patients (Pinkney et al., 2010). In
particular, it is difﬁcult to inform patients about the risk, side-effects
and expected consequences, such as long-term nutritional, medical,
and psychological consequences (Pinkney et al., 2010), e.g., micro-
nutrient depletion requiring meticulous monitoring and lifelong
replacement (Mechanick et al., 2008) or the need to balance freedom
from insulin injections after gastric bypass surgery against the risks of
alternative treatment (Pinkney et al., 2010). Health illiteracy and poor
comprehension of the beneﬁts and risks of surgery can result in
unrealistic expectations and poor decision making (Wee et al., 2009)
which challenge informed consent and result in potential litigation
(Kaufman, McNelis, Slevin, & La Marca, 2006).
3.4.2. Information or marketing?
Information disclosure terminology may become directive: terms
like “diabetes surgery”, “diabetes cure”, “metabolic surgery”, “diabetes
remission”, “resolution”, “quelling”, and “biochemical remission”
(Buchwald et al., 2009; Goldﬁne, Shoelson, & Aguirre, 2009; Pinkney
et al., 2010; Purnell & Flum, 2009; Rubino et al., 2010; Varela, 2011;
Walton & Date, 2011) are not value neutral. Correspondingly, the
scientiﬁc literature is full of claims that bariatric surgery has “dramatic
effects” on diabetes, that it is a “success”, and is a “therapeutic tool”
that “reverses the disease” (Rubino, 2008; Rubino et al., 2010). Failing
to disclose that these claims are still controversial undermines valid
consent. There is an important difference between informing patients
that bariatric surgery is “diabetes treatment” to that it is a form of
“enforced behavioral therapy” which can “require many years of
psychiatric support in behaviour modiﬁcation” (James & Morgan,
2010), where exact indications and contraindications to surgery are
yet not deﬁned (Rubino et al., 2010).
3.4.3. Risk perception and lack of understanding
Studies show that patients undergoing bariatric surgery do not
remember information on potential complications provided to them
before surgery (Madan, Tichansky, & Taddeucci, 2007). Internet
information on bariatric treatment is of variable content and quality
(Nichols & Oermann, 2005). Some forms of bariatric surgery may
change the life of the person substantially: eating habits and other
daily life routines may be altered. Risk related to the surgeon's
experience and the institution's procedural volume (Ballantyne et al.,
2005), as well as surgeons' relationship with industry, is not always
disclosed. Hence, to inform patients about bariatric surgery for T2DM
in an adequate and balancedway seems to be at least as challenging as
in other types of treatment (Sarwer et al., 2004).
3.4.4. Lack of competence to consent
Additionally, a substantial proportion of bariatric surgery candi-
dates have psychological/psychosocial co-morbidity (Roski, 2005;
Sarwer et al., 2004) which may reduce the persons' decision making
competence. Some studies have identiﬁed that as many as 50%–80% of
candidates for bariatric surgery have psychiatric disorders (James &
Morgan, 2010; Roski, 2005; Sarwer et al., 2004). Obtaining a valid
informed consent prior to surgery may therefore be challenging due
to a lack of information and understanding, reduced voluntariness,
and diminished decision making capacity. Existing guidelines may be
valuable for ascertaining valid informed consent (Wee et al., 2009).
3.5. Q5. Does surgery alter the conception of diabetes or diabetic patients?
Surgery appears to change the conception of diabetes: “Whereas
diabetes is traditionally viewed as a chronic, relentless disease in
which delay of end-organ complications is the major treatment goal,GI surgery offers a novel end point: the concept of complete disease
remission” (Rubino et al., 2009). With bariatric surgery, T2DM has
gone from the ingrained notion of being a medical (metabolic)
chronic disease to become a “surgical disease” (Lautz et al., 2011),
which can be resolved by “metabolic surgery” (Rubino, 2008; Rubino
et al., 2010). T2DM is frequently referred to as a “lifestyle disease,” i.e.,
being a behavioral disease with low prestige and subject to stigma. It
is often considered to be self-inﬂicted resulting from lack of self-
control, and is, as such, subject to prejudice (Puhl & Heuer, 2009).
Therefore, surgery may make T2DM more “biological,” enhance its
prestige, and reduce prejudice, discrimination, and stigma.
On the other hand, bariatric surgery has been described as
“surgically induced starvation bymalabsorption or gastric restriction.”
(Pinkney et al., 2010) with social and esthetical signiﬁcance (James &
Morgan, 2010). It may therefore be regarded as a surgical solution to
the medical implications of a social problem. In this perspective bariatric
surgery may support (or even enhance) the stigmatization of a
vulnerable group of people.
The terms diabetes resolution or remission are often based on
surgeons` clinical judgment and have seldom been precisely deﬁned in
the literature. Recently, however, a consensus statementwas published
suggesting that remission is deﬁned as achieving glycaemia below the
diabetic range in the absence of active pharmacologic (anti-hypergly-
cemic medications, immunosuppressive medications) or surgical
therapy (ongoing procedures such as repeated replacements of
endoluminal devices) (Buse et al., 2009). Partial remission is sub-
diabetic hyperglycemia (A1C not diagnostic of diabetes [b6.5%], fasting
glucose 100–125 mg/dl [5.6–6.9 mmol/l]) of at least 1 year's duration
in the absence of active pharmacologic therapy or ongoing procedures.
Complete remission is a return to “normal” measures of glucose
metabolism (A1C in the normal range, fasting glucose b100 mg/dl
[5.6 mmol/l]) of at least 1 year's duration in the absence of active
pharmacologic therapy or ongoing procedures (Buse et al., 2009).
Hence, bariatric surgery may change the biological and social
conception of T2DM. When surgery enhances the biological aspect of
T2DM, this is morally relevant and may avoid prejudice, stigmatiza-
tion, and discrimination.
3.6. Q6. Should there be limits to bariatric surgery for diabetes?
Where should limits be set with respect to patient BMI, age, family
history of diabetes, duration, and severity of disease and risk proﬁle?
These are morally relevant questions which reach beyond the
competence of scientists and surgeons. Other morally challenging
questions are: should we use surgery for the prevention of T2DM in
obese asymptomatic persons or to use it only after some other
intervention has failed (diet, behavioural treatment, or drug regime)
(Institute of Health Economics, 2011)? Should bariatric surgery be
used for children and when can we use it for adolescents?
More knowledge may be obtained by high quality empirical
studies with subgroup analyses. However, even with such knowledge
available, there are no absolute limits in nature. Inclusion criteria and
limits (of age, severity) are based on social aspects including moral
norms and values. We set limits from what we believe can help
people. Accordingly, such moral issues cannot be answered by
professionals alone. Collaborations between patient organizations,
professionals, and health care providers can elaborate guidelines to be
used in individual deliberations in clinical practice.
3.7. Q7. How does bariatric surgery affect the distribution of health care?
Bariatric surgery is costly, but it may save money on a societal level
in several countries (Dixon, Zimmet, Alberti, & FR, 2011; Keating et al.,
2009). There are substantial inequalities in the access to bariatric
surgery (Socioeconomic disparities in eligibility & access to bariatric
surgery: a national population-based analysis). In private health care
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surgery for T2DM, and those who gain access to bariatric surgery are
not always those who are most in need (Flum, Khan, & Dellinger, 2007;
Purnell & Flum, 2009). Men, black and Hispanic individuals with low
income are less likely to undergo bariatric surgery in the United States
(Flum et al., 2007), where 85%–90% of operations are performed on
white women with higher income levels (Flum et al., 2007).
In a publicly funded health care system, bariatric surgery for T2DM
may drain resources from other health needs. Professionals ﬁght for
“their patients” sometimes ignoring other professionals' and patients'
health problems. However, as T2DM is likely to afﬂict ethnic
minorities and those of lower socio-economic status, bariatric surgery
could reduce inequalities and discrimination.
There may be many reasons for the unjust distribution of bariatric
surgery. Too strict inclusion criteria and guidelines, unbalanced
advertisement, and discrimination of gender, ﬁtness, age and
ethnicity by the use of BMI are but three of these. Hence, the issue
of justice is important when offering bariatric surgery for T2DM, and
the solutions may vary with health care system.
3.8. Q8. Is it morally right to ask for further bariatric surgery studies?
As already indicated there is a request for more high quality
studies (Colquitt et al., 2009; Institute of Health Economics, 2011).
“There is currently little or no scientiﬁc or ethical justiﬁcation for
offering bariatric surgery to patients with a BMI b 35 kg/m2 outside
the context of a controlled clinical trial.” (Pinkney et al., 2010) On the
other hand, is it right to conduct and wait for results from randomized
controlled trials when existing studies are convincing, the “success” is
“dramatic” and the operation is “strikingly safe” (Pinkney, 2010b;
Rubino et al., 2010; Rubino et al., 2009)? Consensus statements argue
that bariatric surgery should be offered to those with BMI ≥30 kg/m2
and with T2DM inadequately controlled by lifestyle interventions and
medication (Rubino et al., 2010).
As high quality randomized controlled trials are resource
demanding and time consuming, there is a danger that many
vulnerable patients will be deprived of a treatment which is
documented to be effective by a large number of case series. On
the other hand, it has been argued that most published (positive)
research ﬁndings based on small short-term observational studies
are false (Ioannidis, 2005). Newmethods are introduced into clinical
practice before evidence is available (Ross et al., 2008) and there are
double standards for evidence: “If surgery were a pill, it would be
monitoredmuchmore carefully.” (Pinkney et al., 2010). Studies from
centers with a homogeneous patient group (e.g. private centers)
may lack external validity.
There is therefore a danger of putting a futile or even a detrimental
treatment into clinical practice that later cannot be veriﬁed by
randomized studies because this would be considered unethical
(Hofmann, 2012). Limited understanding of the effects of bariatric
surgery is therefore an ethical problem. History shows that we too
often have been overly optimistic.
4. Discussion
We have identiﬁed several moral challenges related to bariatric
surgery to T2DM for persons with BMI b 35 kg/m2. Some of the most
prominent moral issues are how to: 1. assess the safety and outcome
of bariatric surgery, 2. decide on proper endpoints, 3. obtain informed
consent when information is complex or uncertain or when the
competence is reduced, 4. handle strong stakeholder interests, 5.
handle changes in conceptions of the disease and the patient group, 6
to set limits, 7. provide just distribution of health care, and 8. handle
the lack of knowledge. These challenges seem to result from a lack of
high quality evidence, from disagreement on clinical indications, from
prejudice against persons with “lifestyle diseases,” but also fromtrying to discipline human behavior through surgery. Moreover,
several surgical procedures are available, and strong preferences
among surgeons and patients may hamper high quality research.
Although there are strong and opposing opinions on many of these
issues, there is a large degree of consensus in the literature that these
issues are morally challenging.
Thoughmany morally relevant questions have been identiﬁed, the
current study is not exhaustive, and other relevant questions remain:
Should bariatric surgery be offered to adolescents with T2DM and
BMI b 35 kg/m2 or even children? What is the opportunity cost of
bariatric surgery, and which health services will receive less attention
if bariatric treatment receives more? Which surgical procedures
should be recommended for which patient groups? How should the
various values, interests and perspectives outlined here be balanced?
How should we perform ethically sound research? These and other
morally pertinent questions are beyond the scope of this study and its
method, and should be addressed in the decision making context. The
aim of this study has been to highlight the moral issues relevant for
deliberations on bariatric surgery for T2DM so that informed advice
and sound justiﬁcations can be given and accountable decisions can be
made. Arguments have to be assessed, values weighted and
alternatives appraised in the context of decision making.
Although the selection of questions and moral challenges posed in
this study may not be value neutral (Hofmann, 2005a; Hofmann,
2005b), this review does not represent speciﬁc interests, such as
patient interest groups, surgeons, industry, health insurers, health
policy makers or HTA-agencies. Moreover, other than the selected
moral questions (Q1–8) may be relevant. Of the 32 questions of the
Socratic approach, only those which are reﬂected in the literature, or
which are considered to be controversial by the stakeholders need to be
addressed. Initially 13 questions were identiﬁed as morally relevant.
The literature search did not reveal additional questions, which
indicates that the initial selection was adequate. A second round of
discussion eliminated 5 questions, as they were not considered to be
special to bariatric surgery for T2DM with BMI b 35 kg/m2. Would
other methods have achieved the goals of this study more effectively?
Obviously other approaches to address ethical issues within and
without a health technology assessment setting could have been
applied. Nevertheless, the method applied here is well established for
assessing health technologies and is able to highlight many of the
challenges that are identiﬁed in the literature. It has also been applied
previously to bariatric surgery (Hofmann, 2010).
How good are the sources reviewed in this study? Other sources of
data could have been used, e.g., primary studies with interviews of
eligible persons for bariatric treatment, their relatives, health care
personnel, the health care industry, health insurers and health policy
makers. However, primary research was beyond the scope of this
review.Moreover, as high quality evidence is scarce, studies of inferior
quality have been included in this review. This can of course result in
bias in assessing safety, efﬁcacy, effectiveness, and efﬁciency.
However, these concerns are not that crucial to the review of other
moral challenges and ethical arguments, as relevant challenges and
important and sound arguments may occur in journals and publica-
tions of lower quality.
Are the moral challenges reviewed in this paper speciﬁc to
bariatric surgery for T2DM with BMI b 35 kg/m2? No, but bariatric
surgery is of particular interest, because it uses medical intervention
to alter organs and processes that otherwise appear healthy, and
because we do not know whether it addresses the causes of T2DM.
T2DM is of speciﬁc interest, as it associated with lifestyle and human
behavior. Bariatric surgery has been viewed as an “attempt to combat
an excess of food by cutting out parts of their stomachs and intestines,
and consider this a rational solution” (Pinkney et al., 2010). Surgery
offers symptoms relief, prevents disease progression, but is still
controversial in terms of whether it provides a cure or not (Pinkney,
2010a). Moreover, T2DM is often considered to be a self-inﬂicted
602 B. Hofmann et al. / Journal of Diabetes and Its Complications 27 (2013) 597–603disease resulting from lack of self-control, and is, as such, subject to
prejudice. Many of themoral challenges with BMI b 35 kg/m2 are also
relevant for BMI≥35 kg/m2, but they aremore outspoken for the ﬁrst.
Hence, bariatric surgery for T2DM poses moral challenges that are
known from other ﬁelds of health care, but the combination of
uncertain mechanisms, weak evidence, broad range of endpoints,
complex and uncertain information to patients, as well as the mixture
of behavior and biology is unique.
Again, many of the arguments presented in this study have to be
assessed in detail when deciding on bariatric surgery in particular
contexts. This review highlights the moral issues that are pertinent in
the literature and that may be relevant in order to make transparent
and sound decisions.
5. Conclusions
We have identiﬁed several important moral issues with bariatric
surgery for T2DM for BMI b 35 kg/m2: assessing and informing about
safety and patient outcomes, deﬁning and selecting endpoints,
assessing stakeholder interests, acquiring valid informed consent,
stigmatization, discrimination and just distribution of health care.
These moral challenges are important both on the individual (micro)
level, on the management (meso) level, and on the health policy
making (macro) level. Thus they are relevant for all who advice and
treat persons with T2DM. Many of the identiﬁed challenges result
from the lack of high quality evidence. More high quality evidence is
therefore important to reduce the moral challenges and to make
accountable decisions in diabetes care and in health policy making. In
this review our calling has been “to ask questions, not to give
answers”, to paraphrase the poet Henrik Ibsen.Acknowledgments
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